SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
04 août 2022 16h05 HE
|
SIGA Technologies Inc.
- Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX® Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales – - Received...
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
28 juil. 2022 16h15 HE
|
SIGA Technologies Inc.
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
15 juil. 2022 07h30 HE
|
SIGA Technologies Inc.
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a...
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
12 juil. 2022 16h15 HE
|
SIGA Technologies Inc.
- Approximately $26 Million of Orders Received from Canada underExisting Procurement Contracts –- Approximately $2 Million of Orders Received from Two New Jurisdictions - NEW YORK, July 12,...
SIGA Technologies Receives Approval from UK for Tecovirimat
08 juil. 2022 07h30 HE
|
SIGA Technologies Inc.
NEW YORK, July 08, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
23 juin 2022 08h00 HE
|
SIGA Technologies Inc.
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced...
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
22 juin 2022 10h13 HE
|
SIGA Technologies Inc.
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that its...
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
19 mai 2022 07h30 HE
|
SIGA Technologies Inc.
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
12 mai 2022 16h05 HE
|
SIGA Technologies Inc.
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
SIGA Reports Financial Results for Three Months Ended March 31, 2022
05 mai 2022 16h05 HE
|
SIGA Technologies Inc.
- First Sale of Intravenous (IV) TPOXX® to U.S. Government under the 19C BARDA Contract – - Contract with a New International Jurisdiction for an Initial Order of Approximately $3 Million of Oral...